Gsk (GLAXF) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Gsk (GLAXF) over the last 17 years, with Q2 2025 value amounting to -$11.34.
- Gsk's Debt to Equity changed N/A to -$11.34 in Q2 2025 from the same period last year, while for Jun 2025 it was -$11.34, marking a year-over-year change of. This contributed to the annual value of -$0.94 for FY2024, which is 16955.87% down from last year.
- As of Q2 2025, Gsk's Debt to Equity stood at -$11.34.
- Over the past 5 years, Gsk's Debt to Equity peaked at $1.98 during Q4 2022, and registered a low of -$17.12 during Q1 2021.
- Over the past 5 years, Gsk's median Debt to Equity value was -$0.94 (recorded in 2024), while the average stood at -$3.67.
- In the last 5 years, Gsk's Debt to Equity soared by 2318.96% in 2022 and then plummeted by 16955.87% in 2024.
- Gsk's Debt to Equity (Quarter) stood at $1.61 in 2021, then rose by 23.19% to $1.98 in 2022, then crashed by 31.83% to $1.35 in 2023, then tumbled by 169.56% to -$0.94 in 2024, then crashed by 1108.14% to -$11.34 in 2025.
- Its Debt to Equity stands at -$11.34 for Q2 2025, versus -$0.94 for Q4 2024 and $1.35 for Q4 2023.